Wednesday, 23 September 2020 Subjects beyond the scope of Online Learning
Riya Rajayyan Sunday, 30 August 2020

A look at 5 much awaited vaccines

Riya Rajayyan
Sunday, 30 August 2020

A look at 5 much awaited vaccines

As the cases of the Covid-19 grew these past few months, Scientists have been working on vaccines to help the world come back to life once again. The cases have crossed 24.6M+ as of today with 835K+ deaths.United States has the highest number of cases (6M) followed by Brazil (3.81M) and India (3.46M). Countries like Russia, Peru stand 4th and 5th most infected as well. Although about 16.1M have recovered, the look out for a vaccine which acts as a savior does not end.

There are about 5 vaccines under trial currently.

Firstly, Oxford’s ChAdOx1 nCoV-19. This has been jointly developed by British-Swedish company AstraZeneca and the University of Oxford. The vaccine is made from a genetically engineered virus that causes the common cold in chimpanzees. However, the virus has been modified so that it doesn’t cause infection in people and also to mimic the coronavirus. This was done so that the vaccine resembles the coronavirus and the immune system can learn how to attack it. The estimated price of the vaccine will be $4 (Rs 295).

Secondly, Moderna vaccine, American drug company Moderna’s mRNA-1273 vaccine is in the third phase of its trial. On May 18, the company announced preliminary findings that healthy subjects had responded to its mRNA vaccine by producing “neutralizing antibodies.” The details that Moderna presented suggest that the company may be on licensing the first mRNA vaccine for human use. Its price is expected to be between Rs 1,800 and Rs 2,300.

Thirdly, Vaccine by China’s Sinopharm, A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said. The third phase of this potential vaccine’s trial is underway in the UAE. Two doses of this vaccine will reportedly cost Rs 10,700.

Fourthly, CanSino Biologics Inc’s vaccine Ad5-nCoV, It uses a weakened common cold virus (adenovirus, which infects human cells readily but is incapable of causing disease) to deliver genetic material that codes for the SARS-CoV-2 spike protein to the cells. These cells then produce the spike protein and the immune system creates antibodies that will recognize that spike protein and fight off the coronavirus.There has been no revelation about the price of the vaccine.

And lastly, Sputnik V, Russia has been the first country to grant approval for a COVID-19 vaccine, but the announcement has drawn a mixed response. The vaccine has not yet completed its phase-three trial, which involves wide-scale testing with thousands of participants. The "Sputnik V" is a vaccine developed by the Gamaleya research institute in coordination with the Russian defence ministry. It is based on a proven vaccine against the common cold. Scientists in Russia and elsewhere have questioned the speed of the development and lack of transparency. The price of the vaccine has not been announced yet.

All these vaccines are expected to roll out by the end of this year, hopefully it tackles the problems our world is facing and restores us back to normal.